IRON Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Disc Medicine Inc (IRON) is not a strong buy for a beginner, long-term investor at this moment. While analysts are optimistic with high price targets and positive ratings, the technical indicators, financial performance, and lack of recent positive catalysts suggest a cautious approach. The stock's pre-market price of $71.65 is below key support levels, and the technical trend is weak. Additionally, the options data reflects a slightly bearish sentiment. Given the user's impatience and unwillingness to wait for optimal entry points, holding off for now is recommended.
The MACD histogram is negative and expanding (-0.509), indicating bearish momentum. RSI is neutral at 31.011, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level ($77.154) and is approaching the first support level ($72.062). This suggests potential downside risk.
and positive ratings, citing confidence in the approval of Bitopertin and the company's strong position in addressing unmet medical needs. The stock also has a 9.88% chance of increasing in the next week and 11.48% in the next month.
Technical indicators are bearish, with the stock trading below key support levels. Options data shows a slightly bearish sentiment. Financial performance remains weak, with negative revenue and net income despite YoY improvements. No recent news or congress trading data is available to provide additional positive momentum.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved YoY to -$62.32M (+134.30%), and EPS improved to -1.77 (+98.88%). Despite improvements, the company remains unprofitable, with no gross margin.
Analysts are bullish, with Morgan Stanley, TD Cowen, BMO Capital, and Jefferies maintaining Buy or Overweight ratings. Price targets range from $120 to $154, reflecting confidence in the company's drug approval pipeline and long-term growth potential.
